Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Jones Lang LaSalle Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $69 (market cap $30.93B), while Jones Lang LaSalle Inc trades at $294.36 (market cap $13.58B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.3× Jones Lang LaSalle Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| GEHC | JLL | |
|---|---|---|
Market Cap | $30.93B | $13.58B |
Volume | 5,033,451 | 414,312 |
Sector | Health | Real Estate |
52-Week High | $88.16 | $392.79 |
52-Week Low | $59.48 | $280.16 |
Enterprise Value | $39.39B | $16.34B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 71 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
JLL trades at $298.32, up 0.07% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 14.16 and P/S of 0.51, alongside consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M. Recent news highlights acquisitions and positive growth coverage, while analyst consensus is bullish with a $450.50 price target.
The outlook for JLL is positive based on earnings momentum and attractive valuation, though near-term technical weakness and reliance on real estate market cycles present risks. Upside potential exists if the company maintains its earnings beat streak and capitalizes on data center and global real estate growth trends highlighted in recent analyst reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
